- Home
- USGO vs LPTX Comparison
USGO vs LPTX Comparison
Compare USGO & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- LPTX
- Stock Information
- Founded
- USGO 2015
- LPTX 2011
- Country
- USGO Canada
- LPTX United States
- Employees
- USGO N/A
- LPTX N/A
- Industry
- USGO Precious Metals
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USGO Basic Materials
- LPTX Health Care
- Exchange
- USGO Nasdaq
- LPTX Nasdaq
- Market Cap
- USGO 120.6M
- LPTX 119.6M
- IPO Year
- USGO 2023
- LPTX N/A
- Fundamental
- Price
- USGO $9.18
- LPTX $2.40
- Analyst Decision
- USGO Strong Buy
- LPTX Strong Buy
- Analyst Count
- USGO 1
- LPTX 3
- Target Price
- USGO $26.50
- LPTX $7.50
- AVG Volume (30 Days)
- USGO 22.3K
- LPTX 335.2K
- Earning Date
- USGO 02-19-2025
- LPTX 11-13-2024
- Dividend Yield
- USGO N/A
- LPTX N/A
- EPS Growth
- USGO N/A
- LPTX N/A
- EPS
- USGO N/A
- LPTX N/A
- Revenue
- USGO N/A
- LPTX N/A
- Revenue This Year
- USGO N/A
- LPTX N/A
- Revenue Next Year
- USGO N/A
- LPTX N/A
- P/E Ratio
- USGO N/A
- LPTX N/A
- Revenue Growth
- USGO N/A
- LPTX N/A
- 52 Week Low
- USGO $5.00
- LPTX $1.68
- 52 Week High
- USGO $14.46
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- USGO 53.48
- LPTX 34.52
- Support Level
- USGO $7.26
- LPTX $2.30
- Resistance Level
- USGO $8.80
- LPTX $2.66
- Average True Range (ATR)
- USGO 0.75
- LPTX 0.29
- MACD
- USGO 0.20
- LPTX -0.09
- Stochastic Oscillator
- USGO 77.29
- LPTX 7.82
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .